Eli Lilly is anticipating an exciting year ahead, with a wide variety of pipeline advancements and expected progression within the company. Eli Lilly is shifting to a broader portfolio of medicines across expanded indications, and accelerating its manufacturing capabilities. Additionally, the company is moving past the conventional pharmaceutical model by developing an innovative direct-to-consumer mindset in the form of its LillyDirect Platform to improve access.
Eli Lilly has several significant pipeline assets to improve patient outcomes, with six launches and late-stage programs in development, including tirzepatide and orforglipron, indicated for obesity and weight-loss. The company has also launched six additional early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets. Furthermore, the usage of incretins allows the company to expand into other therapy areas beyond metabolism, such as neuroscience and inflammatory diseases. These pipeline assets are focused on areas such as obesity, diabetes, cardiovascular, renal, and hepatic diseases.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Over 75% of these new medicines are outside of incretins and amylins, further broadening its portfolio, and exploring diseases with significant unmet needs such as elevated lipoprotein(a), chronic pain, early Alzheimer’s disease, and early breast cancer.
In 2024, the demand for Mounjaro and Zepbound was outpacing the supply. As a result, Eli Lilly invested $55bn into the international launches of 13 manufacturing facilities, including API and dry networks, as well as parenteral and device networks that are expected to come online within the next few years.
Eli Lilly has focused on speeding innovation to patients with the usage of its differentiated development engine. This allowed the company to initiate the process of discovery to first launch 3.5 years quicker than the industry, with over 24 new molecular entity launches occurring from 2015–2025. Furthermore, Eli Lilly’s $1bn collaboration with NVIDIA to build a supercomputer allows the company to accelerate molecular simulations, analyse protein structures, and train large scale artificial intelligence (AI) models for drug discovery and clinical research. This further supports Eli Lilly’s commitment to target novel modalities, such as antibody-drug conjugates, small interfering RNA (siRNA), and radioligand therapies. Furthermore, Eli Lilly was involved in 39 transactions in 2025, including with companies such as Scorpion, Verve, Adverum, and SiteOne, and deployed over $4bn in capital in 2025, whilst simultaneously supporting over 180 biotech companies since 2023.
Eli Lilly has broken away from its period of uncertainty by solving supply issues, and strengthening and expanding its portfolio in a wide range of therapy areas, with the aim to improve patient outcomes on an international scale.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
